Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to test if talazoparib is safe and evaluate its response to
advanced breast cancer associated with mutation of gene called PALB.